{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Treatment of Hepatitis C Virus: An Update on Medications and Patient Education

Activity Steps


This article has been approved by the Orthopaedic Nurses Certification Board for Category B credit toward recertification as an ONC.

Purpose of Activity

To provide information on direct-acting antiviral (DAA) medications to treat infection from the hepatitis C virus (HCV).

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Recognize risks and adverse effects commonly associated with DAA for HCV treatment.
  2. Outline issues related to the use of DAA, including the dosing and administration of the drugs.
Price: $15.00


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours (APH)

Test Code: ON0719C
Published: Jul/Aug 2019
Expires: 6/4/2021
Passing Score: 14/20 (70%)
Authors: Suzanne Molino, PharmD, BCPS; Jessica Cottreau, PharmD, BCPS
Topics: Hepatitis C